Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening
Abstract Organoids are three‐dimensional cell aggregates with near‐physiologic cell behaviors and can undergo long‐term expansion in vitro. They are amenable to high‐throughput drug screening processes, which renders them a viable preclinical model for drug development. The procedure of organoid‐bas...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | View |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/VIW.20230010 |
| _version_ | 1827576982508929024 |
|---|---|
| author | Siqi Zhang Jieting Shen Xingkai Wang Xiaona Sun Yuxuan Wu Ming‐Rong Zhang Rui Wang Kuan Hu |
| author_facet | Siqi Zhang Jieting Shen Xingkai Wang Xiaona Sun Yuxuan Wu Ming‐Rong Zhang Rui Wang Kuan Hu |
| author_sort | Siqi Zhang |
| collection | DOAJ |
| description | Abstract Organoids are three‐dimensional cell aggregates with near‐physiologic cell behaviors and can undergo long‐term expansion in vitro. They are amenable to high‐throughput drug screening processes, which renders them a viable preclinical model for drug development. The procedure of organoid‐based high‐throughput screening has been extensively employed to discover small‐molecule drugs, encompassing the steps of generating organoids, examining efficient drugs in organoid cultures, and data assessment. Compared to small molecules, peptides are more straightforward to synthesize, can be modified chemically, and demonstrate high target specificity and low cytotoxicity. Therefore, they have emerged as promising carriers to deliver drugs to disease‐associated targets and could be efficient therapeutic drugs for various diseases. To date, organoids have been used to evaluate the efficacy of certain peptide agents; however, no organoid‐based high‐throughput screening of peptide drugs has been reported. Given the advantages of peptide drugs, there is an urgent need to establish organoid‐based peptide high‐throughput screening platforms. In this review, we discuss the typical approach of screening small‐molecular drugs with the use of organoid cultures, as well as provide an overview of the studies that have incorporated organoids in peptide research. Drawing on the knowledge from small molecular screens, we explore the difficulties and potential avenues for creating new platforms to identify peptide agents using organoid models. |
| first_indexed | 2024-03-08T21:20:16Z |
| format | Article |
| id | doaj.art-599303c6004f4976ac6b8f7fcff4ccee |
| institution | Directory Open Access Journal |
| issn | 2688-3988 2688-268X |
| language | English |
| last_indexed | 2024-03-08T21:20:16Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | View |
| spelling | doaj.art-599303c6004f4976ac6b8f7fcff4ccee2023-12-21T10:46:40ZengWileyView2688-39882688-268X2023-12-0146n/an/a10.1002/VIW.20230010Integration of organoids in peptide drug discovery: Rise of the high‐throughput screeningSiqi Zhang0Jieting Shen1Xingkai Wang2Xiaona Sun3Yuxuan Wu4Ming‐Rong Zhang5Rui Wang6Kuan Hu7State Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College BeijingChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College BeijingChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College BeijingChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College BeijingChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College BeijingChinaDepartment of Advanced Nuclear Medicine Sciences Institute of Quantum Medical Science National Institutes for Quantum Science and Technology ChibaJapanState Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College BeijingChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College BeijingChinaAbstract Organoids are three‐dimensional cell aggregates with near‐physiologic cell behaviors and can undergo long‐term expansion in vitro. They are amenable to high‐throughput drug screening processes, which renders them a viable preclinical model for drug development. The procedure of organoid‐based high‐throughput screening has been extensively employed to discover small‐molecule drugs, encompassing the steps of generating organoids, examining efficient drugs in organoid cultures, and data assessment. Compared to small molecules, peptides are more straightforward to synthesize, can be modified chemically, and demonstrate high target specificity and low cytotoxicity. Therefore, they have emerged as promising carriers to deliver drugs to disease‐associated targets and could be efficient therapeutic drugs for various diseases. To date, organoids have been used to evaluate the efficacy of certain peptide agents; however, no organoid‐based high‐throughput screening of peptide drugs has been reported. Given the advantages of peptide drugs, there is an urgent need to establish organoid‐based peptide high‐throughput screening platforms. In this review, we discuss the typical approach of screening small‐molecular drugs with the use of organoid cultures, as well as provide an overview of the studies that have incorporated organoids in peptide research. Drawing on the knowledge from small molecular screens, we explore the difficulties and potential avenues for creating new platforms to identify peptide agents using organoid models.https://doi.org/10.1002/VIW.20230010high‐throughput screeningorganoidspeptide‐based radiopharmaceuticalspeptide–drug conjugatestherapeutic peptides |
| spellingShingle | Siqi Zhang Jieting Shen Xingkai Wang Xiaona Sun Yuxuan Wu Ming‐Rong Zhang Rui Wang Kuan Hu Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening View high‐throughput screening organoids peptide‐based radiopharmaceuticals peptide–drug conjugates therapeutic peptides |
| title | Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening |
| title_full | Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening |
| title_fullStr | Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening |
| title_full_unstemmed | Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening |
| title_short | Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening |
| title_sort | integration of organoids in peptide drug discovery rise of the high throughput screening |
| topic | high‐throughput screening organoids peptide‐based radiopharmaceuticals peptide–drug conjugates therapeutic peptides |
| url | https://doi.org/10.1002/VIW.20230010 |
| work_keys_str_mv | AT siqizhang integrationoforganoidsinpeptidedrugdiscoveryriseofthehighthroughputscreening AT jietingshen integrationoforganoidsinpeptidedrugdiscoveryriseofthehighthroughputscreening AT xingkaiwang integrationoforganoidsinpeptidedrugdiscoveryriseofthehighthroughputscreening AT xiaonasun integrationoforganoidsinpeptidedrugdiscoveryriseofthehighthroughputscreening AT yuxuanwu integrationoforganoidsinpeptidedrugdiscoveryriseofthehighthroughputscreening AT mingrongzhang integrationoforganoidsinpeptidedrugdiscoveryriseofthehighthroughputscreening AT ruiwang integrationoforganoidsinpeptidedrugdiscoveryriseofthehighthroughputscreening AT kuanhu integrationoforganoidsinpeptidedrugdiscoveryriseofthehighthroughputscreening |